'Attack JAK': Ajax secures $95M to test new JAK2 inhibitorJAK2 inhibitor after industry's string of myelofibrosis deals
13 May 2024
PROTACs
A large pharma company wanted to buy Ajax Therapeutics when it was raising a $40 million Series B in 2021. But the startup thought it could do better on its own.
“We thought that the compound at the time, which was part of the abstract in our 2022 ASH presentation, was a progenitor of what we’ve developed today. So we’ve actually made it better,” CEO Martin Vogelbaum told Endpoints News. “And we felt we were the team that could make it better and get to the best compound that we could take into the clinic.”
Preview
Source: EndPoints
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
SIGN UP
LOG IN
BECOME A PREMIUM SUBSCRIBER
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
Drugs
Chat with Hiro
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.